Pyrrolo[2,3-d]pyrimidines active as Btk inhibitors

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Expert Opinion on Therapeutic Patents

• Publication date

  2017-07-20

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1080/13543776.2017.1355908PMID 28705083
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• New insights in the structure-activity relationships of 2-phenylamino-substituted benzothiopyrano[4,3-d]pyrimidines as kinase inhibitors.

  2018cited by this paper
• Pyrrolo[2,3-d]Pyrimidines as Kinase Inhibitors.

  2017cited by this paper
• Current Status of Bruton’s Tyrosine Kinase Inhibitor Development and Use in B-Cell Malignancies

  2017cited by this paper
• Safety, pharmacokinetics, and pharmacodynamics of BMS-986142, a novel reversible BTK inhibitor, in healthy participants

  2017cited by this paper
• Ibrutinib in CLL: a focus on adverse events, resistance, and novel approaches beyond ibrutinib

  2017cited by this paper
• Discovery and evaluation of 1H-pyrrolo[2,3-b]pyridine based selective and reversible small molecule BTK inhibitors for the treatment of rheumatoid arthritis.

  2017cited by this paper
• Ability of Bruton’s Tyrosine Kinase Inhibitors to Sequester Y551 and Prevent Phosphorylation Determines Potency for Inhibition of Fc Receptor but not B-Cell Receptor Signaling

  2017cited by this paper
• Acquired mutations associated with ibrutinib resistance in Waldenström macroglobulinemia.

  2017cited by this paper
• SLP76 integrates into the B-cell receptor signaling cascade in chronic lymphocytic leukemia cells and is associated with an aggressive disease course

  2016cited by this paper
• Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia.

  2016cited by this paper
• Discovery of highly potent and selective Bruton's tyrosine kinase inhibitors: Pyridazinone analogs with improved metabolic stability.

  2016cited by this paper
• A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies.

  2016cited by this paper
• Btk inhibition treats TLR7/IFN driven murine lupus.

  2016cited by this paper
• Classification of small molecule protein kinase inhibitors based upon the structures of their drug-enzyme complexes.

  2016cited by this paper
• X-Linked Agammagobulinemia in a Large Series of North African Patients: Frequency, Clinical Features and Novel BTK Mutations

  2016cited by this paper
• Discovery of a BTK/MNK dual inhibitor for lymphoma and leukemia

  2016cited by this paper
• Battling Btk Mutants With Noncovalent Inhibitors That Overcome Cys481 and Thr474 Mutations.

  2016cited by this paper
• HM71224, a novel Bruton’s tyrosine kinase inhibitor, suppresses B cell and monocyte activation and ameliorates arthritis in a mouse model: a potential drug for rheumatoid arthritis

  2016cited by this paper
• Identification of a structurally novel BTK mutation that drives ibrutinib resistance in CLL

  2016influential reference
• Bruton's Tyrosine Kinase Deficiency Inhibits Autoimmune Arthritis in Mice but Fails to Block Immune Complex–Mediated Inflammatory Arthritis

  2016cited by this paper
• Discovery of 6-Fluoro-5-(R)-(3-(S)-(8-fluoro-1-methyl-2,4-dioxo-1,2-dihydroquinazolin-3(4H)-yl)-2-methylphenyl)-2-(S)-(2-hydroxypropan-2-yl)-2,3,4,9-tetrahydro-1H-carbazole-8-carboxamide (BMS-986142): A Reversible Inhibitor of Bruton's Tyrosine Kinase (BTK) Conformationally Constrained by Two Locked

  2016cited by this paper
• The BTK Inhibitor, Bgb-3111, Is Safe, Tolerable, and Highly Active in Patients with Relapsed/ Refractory B-Cell Malignancies: Initial Report of a Phase 1 First-in-Human Trial

  2015cited by this paper
• Abstract 2596: ACP-196: a novel covalent Bruton's tyrosine kinase (Btk) inhibitor with improved selectivity and in vivo target coverage in chronic lymphocytic leukemia (CLL) patients

  2015cited by this paper
• Prolonged and tunable residence time using reversible covalent kinase inhibitors

  2015cited by this paper
• Discovery of novel Bruton's tyrosine kinase (BTK) inhibitors bearing a pyrrolo[2,3-d]pyrimidine scaffold.

  2015cited by this paper
• Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia.

  2015cited by this paper
• The drug–target residence time model: a 10-year retrospective

  2015cited by this paper
• Potent and selective Bruton's tyrosine kinase inhibitors: discovery of GDC-0834.

  2015cited by this paper
• Abstract C186: SNS-062 is a potent noncovalent BTK inhibitor with comparable activity against wild type BTK and BTK with an acquired resistance mutation

  2015cited by this paper
• ACP-196 Is a Second Generation Inhibitor of Bruton Tyrosine Kinase (BTK) with Enhanced Target Specificity

  2015cited by this paper
• Abstract 2597: BGB-3111 is a novel and highly selective Bruton's tyrosine kinase (BTK) inhibitor

  2015cited by this paper
• FDA expands approved use of Imbruvica for rare form of non-Hodgkin lymphoma

  2015cited by this paper
• Purine derivatives as potent Bruton's tyrosine kinase (BTK) inhibitors for autoimmune diseases.

  2014cited by this paper
• Targeting Btk/Etk of prostate cancer cells by a novel dual inhibitor

  2014cited by this paper
• Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib.

  2014cited by this paper
• Novel fused pyrimidine compound or a salt thereof

  2014cited by this paper
• Targeting Bruton's tyrosine kinase in B cell malignancies

  2014cited by this paper
• Bruton's TK inhibitors: structural insights and evolution of clinical candidates.

  2014cited by this paper
• Inhibition of Btk with CC-292 Provides Early Pharmacodynamic Assessment of Activity in Mice and Humans

  2013cited by this paper
• Ibrutinib and novel BTK inhibitors in clinical development

  2013cited by this paper
• Inhibitors of bruton's tyrosine kinase

  2013cited by this paper
• Regulatory Phosphorylation of Ikaros by Bruton's Tyrosine Kinase

  2013cited by this paper
• Reversible covalent pyrrolo- or pyrazolopyrimidines useful for the treatment cancer and autoimmune diseases

  2013cited by this paper
• Substituted n-(3-(pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase btk inhibitors

  2013cited by this paper
• Novel pyrrolo pyrimidine derivatives

  2012cited by this paper
• Abstract 2021: ONO-WG-307, a novel, potent and selective inhibitor of Bruton's tyrosine kinase (Btk), results in sustained inhibition of the ERK, AKT and PKD signaling pathways

  2012cited by this paper
• Btk levels set the threshold for B-cell activation and negative selection of autoreactive B cells in mice.

  2012cited by this paper
• Reversible targeting of noncatalytic cysteines with chemically tuned electrophiles

  2012cited by this paper
• Significant Species Difference in Amide Hydrolysis of GDC-0834, a Novel Potent and Selective Bruton's Tyrosine Kinase Inhibitor

  2011cited by this paper
• Heterocyclic compounds and uses thereof

  2011cited by this paper
• Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis.

  2011cited by this paper
• Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765.

  2011cited by this paper
• Clinical Development of AVL-292; A Potent, Selective Covalent Btk Inhibitor for the Treatment of B Cell Malignancies,

  2011cited by this paper
• Antiarthritis Effect of a Novel Bruton's Tyrosine Kinase (BTK) Inhibitor in Rat Collagen-Induced Arthritis and Mechanism-Based Pharmacokinetic/Pharmacodynamic Modeling: Relationships between Inhibition of BTK Phosphorylation and Efficacy

  2011influential reference
• Insights into the conformational flexibility of Bruton's tyrosine kinase from multiple ligand complex structures

  2011cited by this paper
• Structures of human Bruton's tyrosine kinase in active and inactive conformations suggest a mechanism of activation for TEC family kinases

  2010cited by this paper
• Bruton’s tyrosine kinase (Btk): function, regulation, and transformation with special emphasis on the PH domain

  2009cited by this paper
• Bruton's tyrosine kinase and phospholipase Cgamma2 mediate chemokine-controlled B cell migration and homing.

  2007cited by this paper
• Discovery of Selective Irreversible Inhibitors for Bruton’s Tyrosine Kinase

  2007cited by this paper
• Inhibitors of bruton's tyrosine kinase

  2006cited by this paper
• Reduced Dosage of Bruton’s Tyrosine Kinase Uncouples B Cell Hyperresponsiveness from Autoimmunity in lyn−/− Mice1

  2003influential reference
• Bruton's tyrosine kinase is a Toll/interleukin-1 receptor domain-binding protein that participates in nuclear factor kappaB activation by Toll-like receptor 4.

  2003cited by this paper
• Bruton's Tyrosine Kinase Is a Toll/Interleukin-1 Receptor Domain-binding Protein That Participates in Nuclear Factor κB Activation by Toll-like Receptor 4*

  2003cited by this paper
• Crystal structure of Bruton's tyrosine kinase domain

  2002cited by this paper
• Role of Bruton's Tyrosine Kinase in B Cell Development

  2001cited by this paper
• The Tec family of cytoplasmic tyrosine kinases: mammalian Btk, Bmx, Itk, Tec, Txk and homologs in other species

  2001cited by this paper
• Crystal Structure of Bruton's Tyrosine Kinase Domain Suggests a Novel Pathway for Activation and Provides Insights into the Molecular Basis of X-linked Agammaglobulinemia*

  2001cited by this paper
• BLNK mediates Syk-dependent Btk activation

  2001cited by this paper
• Interaction between the Btk PH Domain and Phosphatidylinositol-3,4,5-trisphosphate Directly Regulates Btk*

  2001influential reference
• Signaling network of the Btk family kinases

  2000cited by this paper
• Identification of the SH2 domain binding protein of Bruton's tyrosine kinase as BLNK--functional significance of Btk-SH2 domain in B-cell antigen receptor-coupled calcium signaling.

  1999cited by this paper
• Phosphatidylinositol 3-Kinase-dependent Membrane Association of the Bruton’s Tyrosine Kinase Pleckstrin Homology Domain Visualized in Single Living Cells*

  1999cited by this paper
• The Department of Health and Human Services.

  1999cited by this paper
• Molecular cloning of a docking protein, BRDG1, that acts downstream of the Tec tyrosine kinase.

  1999cited by this paper
• Bruton's tyrosine kinase (BTK) as a dual-function regulator of apoptosis.

  1998cited by this paper
• Regulation of Btk function by a major autophosphorylation site within the SH3 domain.

  1996cited by this paper
• A role for Bruton's tyrosine kinase in B cell antigen receptor-mediated activation of phospholipase C-gamma 2

  1996influential reference
• Activation of BTK by a Phosphorylation Mechanism Initiated by SRC Family Kinases

  1996cited by this paper
• Activation of Bruton's tyrosine kinase (BTK) by a point mutation in its pleckstrin homology (PH) domain.

  1995cited by this paper
• Tec homology (TH) adjacent to the PH domain

  1994cited by this paper
• Expression of Bruton's agammaglobulinemia tyrosine kinase gene, BTK, is selectively down-regulated in T lymphocytes and plasma cells.

  1994cited by this paper
• Deficient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemia.

  1993cited by this paper
• The gene involved in X-linked agammaglobulinaemia is a member of the src family of protein-tyrosine kinases

  1993cited by this paper
• Agammaglobulinemia.

  1952cited by this paper

• Tetrahydrobenzofuro[3,2-b]quinoline: A dual-acting autophagy-dependent DHODH inhibitor that provokes ferroptosis in lung cancer cells.

  2025cites this paper
• Pd-Catalyzed Site-Selective Arene Ortho C–H Chlorination of 4-Aryl-pyrrolo[2,3-d]pyrimidines with para-Toluenesulfonyl Chloride

  2025cites this paper
• Modulating the Binding Kinetics of Bruton's Tyrosine Kinase Inhibitors through Transition-State Effects.

  2025cites this paper
• K2S2O8 Promoted C-H Direct Thiocyanation of Pyrrolo[2,3-d]pyrimidine Derivatives with Ammonium Thiocyanate

  2024cites this paper
• The Application of pyrrolo[2, 3-d]pyrimidine scaffold in medicinal chemistry from 2017 to 2021.

  2023cites this paper
• Approved Small-Molecule ATP-Competitive Kinases Drugs Containing Indole/Azaindole/Oxindole Scaffolds: R&D and Binding Patterns Profiling

  2023cites this paper
• An Appraisal on Synthetic and Medicinal Aspects of Fused Pyrimidines as Anti Neoplastic Agents.

  2022cites this paper
• Transition-metal-free highly regioselective C–H acetoxylation of pyrrolo[2,3-d]pyrimidine derivatives

  2020cites this paper
• Identification of N-phenyl-7H-pyrrolo[2,3-d] pyrimidin-4-amine Derivatives as Novel, Potent, and Selective NF-κB Inducing Kinase (NIK) Inhibitors for the Treatment of Psoriasis.

  2020cites this paper
• Pd-Catalyzed highly selective and direct ortho C–H arylation of pyrrolo[2,3-d]pyrimidine derivatives

  2020cites this paper
• An Expeditious Total Synthesis of 5′-Deoxy-toyocamycin and 5′-Deoxysangivamycin

  2019cites this paper
• Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton's Tyrosine Kinase Inhibitor in Early Clinical Development.

  2018cites this paper
• Kinase Inhibitors for the Treatment of Immunological Disorders: Recent Advances.

  2018cites this paper